Clinical translation of folate receptor-targeted therapeutics.
BACKGROUND
Folate receptor-α (FR-α) has been established as a membrane marker for ovarian cancer. In addition, it is frequently overexpressed in other major types of epithelial tumors. FR-α-based tumor-targeted therapy and drug carriers have been an active area of laboratory research for more than 20 years. Recently, there has been a great increase in the effort to finally translate this promising technology into the clinic and bring FR-targeted therapeutics into the market.


METHODS
Two FR-targeted therapeutic agents have moved into Phase III clinical trials, the monoclonal antibody farletuzumab and the low molecular weight vintafolide, combined with etarfolatide as a companion imaging agent, representing two alternative strategies for targeting the FR.


CONCLUSIONS
Each of the two strategies has advantages and disadvantages. Identification of the best target patient population is likely critical to the ultimate success of FR-targeted agents in the clinic. A successful clinical strategy may require the integration between FR expression analysis and an optimal combination of FR-targeted therapy and standard chemotherapy. Advancement into Phase III trials and the ongoing clinical development of several additional folate conjugates are likely to usher in a new era of clinical translation and validation of FR-targeted imaging and therapeutic agents.
Jilin University, Institute of Life Sciences, Changchun, Jilin, China.
Lesheng
L
Teng
Jing
J
Xie
Lirong
L
Teng
Robert J
RJ
Lee
D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D002352:Carrier Proteins; D002986:Clinical Trials as Topic; D003952:Diagnostic Imaging; D016503:Drug Delivery Systems; D005260:Female; D058973:Folate Receptors, GPI-Anchored / Q000037:antagonists & inhibitors; D005492:Folic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives*; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011956:Receptors, Cell Surface / Q000378:metabolism; D014748:Vinca Alkaloids / Q000008:administration & dosage*
D061067:Antibodies, Monoclonal, Humanized; D002352:Carrier Proteins; C520389:EC145; D058973:Folate Receptors, GPI-Anchored; D011956:Receptors, Cell Surface; D014748:Vinca Alkaloids; C527484:farletuzumab; D005492:Folic Acid